Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of protection against infection and disease is reached 15-21 daysafter the first dose. Protection increased most rapidly against hospitalization and death and slowest against B.1.351infection.While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccinedosein situations of limited vaccine suppliesand high incidences
Highlights • SARS-CoV-2 infection after the first BNT162b2 dose does not boost antibody response. ...
: The efficacy of the first schedule of COVID-19 mRNA vaccines has decreased after the surge of the ...
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the ...
The World Health Organization declared COVID-19 a worldwide pandemic in early 2020 and SARS-CoV-2 in...
BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SA...
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across cou...
BACKGROUND Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) v...
A distinctive feature of the roll out of vaccination against SARS-CoV-2 virus in the UK was the deci...
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a ...
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting...
BACKGROUND: Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical miti...
Updated Dec. 22, 2020Name: BNT162b2Manufacturer: Pfizer, Inc., and BioNTechType of vaccine: mRNAmRNA...
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test...
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the om...
Two of the Coronavirus Disease 2019 (COVID-19) vaccines currently approved in the United States requ...
Highlights • SARS-CoV-2 infection after the first BNT162b2 dose does not boost antibody response. ...
: The efficacy of the first schedule of COVID-19 mRNA vaccines has decreased after the surge of the ...
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the ...
The World Health Organization declared COVID-19 a worldwide pandemic in early 2020 and SARS-CoV-2 in...
BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SA...
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across cou...
BACKGROUND Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) v...
A distinctive feature of the roll out of vaccination against SARS-CoV-2 virus in the UK was the deci...
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a ...
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting...
BACKGROUND: Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical miti...
Updated Dec. 22, 2020Name: BNT162b2Manufacturer: Pfizer, Inc., and BioNTechType of vaccine: mRNAmRNA...
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test...
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the om...
Two of the Coronavirus Disease 2019 (COVID-19) vaccines currently approved in the United States requ...
Highlights • SARS-CoV-2 infection after the first BNT162b2 dose does not boost antibody response. ...
: The efficacy of the first schedule of COVID-19 mRNA vaccines has decreased after the surge of the ...
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the ...